Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0G5PF
|
||||
| Former ID |
DNCL003108
|
||||
| Drug Name |
AFQ056
|
||||
| Synonyms |
Mavoglurant
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Fragile X syndrome [ICD9: 332, 759.83; ICD10:F02.3, G20, Q99.2] | Phase 2/3 | [1], [2] | ||
| Company |
Novartis
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C19H23NO3
|
||||
| InChI |
InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1
|
||||
| InChIKey |
ZFPZEYHRWGMJCV-ZHALLVOQSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Metabotropic glutamate receptor 5 | Target Info | Modulator | [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Long-term potentiation | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Huntington's disease | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Metabotropic glutamate receptor group III pathway | |||||
| Metabotropic glutamate receptor group I pathway | |||||
| Endogenous cannabinoid signaling | |||||
| Reactome | G alpha (q) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| GPCRs, Class C Metabotropic glutamate, pheromone | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01433354) Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label). U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7586). | ||||
| REF 3 | Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.